Related Experiment Videos
Clinical experience with activated factor VII: focus on safety aspects
1University of North Carolina School of Medicine, Division of Hematology/Oncology, Chapel Hill 27599-7035, USA. hrr@med.unc.edu
Summary
Recombinant activated factor VII (rFVIIa) is a safe and effective treatment for hemophilia patients with inhibitors. Adverse events are minimal, with rare thromboembolic complications observed in extensive global use.
Area of Science:
- Hematology
- Pharmacology
- Biotechnology
Background:
- Recombinant activated factor VII (rFVIIa) is utilized globally for treating hemophilia patients with inhibitors to factor VIII (FVIII) or FIX.
- It is also employed for various other medical conditions.
Purpose of the Study:
- To evaluate the safety and efficacy of recombinant activated factor VII (rFVIIa) in clinical practice.
- To assess the incidence of adverse events and thromboembolic complications associated with rFVIIa treatment.
Main Methods:
- Review of over 1500 treated bleeding episodes and surgical procedures involving rFVIIa.
- Analysis of reported serious adverse events and antibody development in patients treated with rFVIIa.
Main Results:
- rFVIIa has been used extensively, treating over 1500 bleeding episodes and supporting numerous surgical procedures.
- Serious adverse events possibly related to rFVIIa infusion occurred in less than 1% of patients.
- No antibodies to FVII were detected, except in one patient with FVII deficiency.
- Thromboembolic complications were rare.
Conclusions:
- Recombinant activated factor VII (rFVIIa) demonstrates a favorable safety profile with minimal side effects.
- The product is considered very safe for treating hemophilic patients with inhibitors and other conditions.
- rFVIIa is effective in managing bleeding episodes and facilitating surgical interventions.